Company Filing History:
3 out of 52 
3 out of 2,405 
Years Active: 2024-2025
Title: Inventor Milan Blanusa: Pioneering Cancer Therapies
Introduction
Milan Blanusa is a distinguished inventor based in Jena, Germany, known for his significant contributions to the field of immunology and cancer research. With two patents to his name, he has been at the forefront of innovation, developing therapies that aim to combat cancer through targeted antibody technology.
Latest Patents
Milan's latest patents include innovative developments in anti-ILT4 antibodies and antigen-binding fragments. These inventions provide new mechanisms for binding to ILT4 (immunoglobulin-like transcript 4), offering potential combinations with anti-PD1 antibodies. The applications of these antibodies extend to methods for treating or preventing cancer in subjects, showcasing a promising avenue for therapeutic intervention. Additionally, Milan outlines sophisticated methods for producing these antibodies and fragments, contributing to the advancement of medical treatments.
Career Highlights
Throughout his career, Milan has collaborated with prominent organizations in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Agenus Inc. His experience in these firms has enriched his expertise in drug development and biomedical research, helping him translate scientific discoveries into practical solutions for healthcare.
Collaborations
Milan has had the opportunity to work alongside notable colleagues such as Barbara Joyce-Shaikh and Andrea Claudia Schuster. These collaborations have fostered an environment of innovation and mutual support, propelling advancements in their respective fields and promoting synergy in research and development.
Conclusion
Milan Blanusa stands out as a significant figure in the realm of invention, with a clear focus on enhancing cancer treatment through innovative approaches. His work with antibodies and antigen-binding fragments positions him as a key player in the ongoing fight against cancer, ensuring that his contributions will have lasting impacts on the future of therapeutic interventions.